<DOC>
	<DOCNO>NCT01716611</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety management hyponatremia ascites patient liver cirrhosis .</brief_summary>
	<brief_title>Tolvaptan Hyponatremia Cirrhotic Patients With Ascites</brief_title>
	<detailed_description>Patients advance cirrhosis frequently develop dilutional hyponatremia due impairment renal ability eliminate solute-free water . Although pathophysiology disorder multifactorial , increased hypersecretion arginine vasopressin ( AVP ) major factor . The prevalence hyponatremia cirrhosis , define serum sodium level 130 mmol/L report 20 % , several line evidence hyponatremia risk factor development hepatic encephalopathy , predict poor quality life independent liver function . Hyponatremia also predict short-term mortality cirrhotic patient await liver transplantation . The principle management hypervolemic hypona- tremia induce negative water balance , aim normalizing increase total body water , would result improvement serum sodium concentration . Fluid restriction widely accept nonpharmacological therapy , efficacy limit . The administration hypertonic sodium chloride common severe hypervolemic hyponatremia , effect partial short live ; moreover , additional expansion fluid worsen ascites edema . Therefore , pathophysiologically orient treatment hyponatremia focus inhibit action AVP . Recently , antagonist V2 receptor vasopressin propose manage hyponatremic patient , heart fauilure , syndrome inappropriate antidiuretic hormone liver cirrhosis . Especially , lot hyponatremic patient cirrhosis ascites , intractable ascites . In patient , antagonist V2 receptor vasopressin include tolvaptan might beneficial effect enhance hyponatremia , also ascites</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . 20 year age old 2 . Patients cirrhosis diagnose liver biopsy combination laboratory ( thrombocytopenia ) , radiologic ( cirrhotic feature liver , splenomegaly , collateral shunt US , CT , MRI ) endoscopic finding ( gastoesophageal varix portal hypertensive gastropathy ) 3 . ≥ Grade 2 ascites already treat restrict salt diet within 3 month 4 . Hyponatremia ( Serum sodium ≥120 mEq/L ≤130 mEq/L ) 5 . Written inform consent 1 . Hypovolemic hyponatremia ( Patients hypotension chronic heart failure ) 2 . Serum potassium concentration &gt; 5.5 mEq/L 3 . Serum bilirubin &gt; 5.0 mg/dL 4 . Blood coagulation factor &lt; 40 % international normalize ratio ( INR ) &gt; 2.3 5 . Platelet count &lt; 30,000/mm3 6 . Serum creatinine &gt; 3 mg/dL 7 . Treatment within 2 week vasopressin anlogues 8 . Systolic blood pressure &lt; 80 mmHg 9 . History gastrointestinalesophageal varix bleed variceal hemorrhage 10 . Spontaneous bacterial peritonitis 11 . Hepatic encephalopathy ≥ grade 3 12 . History Hepatocellular carcinoma treatment within 3month viable tumor Viable hepatocellular carcinoma 13 . Liver transplant 14 . Previous treatment transjugular intrahepatic portosystemic stent shunt ( TIPS ) 15 . History significant cardiac disease recent myocardial infarction ischemic disease within 1 year screen 16 . Prolonged QTc interval &gt; 500 m base electrocardiography 17 . Treatment within 2 week substance drug may either induce significantly inhibit cytochrome P450 3A ( ketoconazole , clarithromycin , erythromycin , fluconazole , diltiazem , verapamil , etc ) 18 . Pregnant breast feed 19 . Patients galactose intolerance malabsorption ( production drug contains lactose ) 20 . HbA1Cc ≥ 9 % 21 . Serious medical illness ( e.g . heart failure , severe pulmonary disorder , alcohol dependence , malignant tumor , etc )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>liver cirrhosis</keyword>
	<keyword>hyponatemia</keyword>
	<keyword>ascites</keyword>
	<keyword>vaptans</keyword>
	<keyword>antidiuretic hormon</keyword>
	<keyword>arginine vasopressin</keyword>
</DOC>